-AAIC, together with Ohara Pharmaceutical Co., Ltd. and others, makes additional investment in MYDAWA-

MYDAWA (headquarters: Nairobi, Kenya; CEO: Tony Wood), an investment destination of the Africa Healthcare Fund (AHF1) and Africa Innovation & Healthcare Fund（AHF2）managed by AAIC Investment Pte. Ltd. (headquarters: Singapore; CEO: Susumu Tsubaki; hereinafter referred to as ” AAIC”), announced in May 2025 that it had completed a fundraising of US$9.6 million (approximately 1.49 billion yen).

AAIC has been investing in MYDAWA since 2019, and in this latest round of funding, it has made additional investments together with the Danish government-affiliated financial institution IFU (Investment Fund for Developing Countries), private equity funds Alta Semper Capital and Creadev, and Ohara Pharmaceutical Co., Ltd.

Founded in Kenya in 2017, MYDAWA is a Healthtech company that operates a hybrid pharmaceutical e-commerce and pharmacy platform, providing integrated online medical consultations, e-prescriptions, testing services, chronic disease management, and pharmaceutical delivery.

With this funding, MYDAWA plans to further expand its ” bricks-and-clicks ” pharmacy model, which combines online and offline services, and plans to open 30 new stores in Uganda and 10 new stores in Kenya, aiming to serve more than 8 million patients per year by 2032.

The company also plans to use AI technology to optimize inventory management, streamline service provision, and reduce the burden on patients. These improvements are expected to lead to improved supply chain efficiency and service quality.

AAIC will continue to contribute to realizing better access to medical care in Africa by investing in startups that meet local needs and support sustainable growth in the healthcare sector.

For queries related to this press release
AAIC Investment Pte. Ltd.
Hiroki ISHIDA
Representative of Kenya office and Director of Egypt Office
pr-investment@ aa-ic.com, pa@ aa-ic.com
(Please remove the space behind@ when enquiring via email)